Citius Oncology Inc (CTOR)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Citius Oncology Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.

Citius Oncology is a biopharmaceutical company that develops and commercializes targeted oncology therapies. Its lead product is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein approved by the FDA for treating patients with persistent or recurrent cutaneous T-cell lymphoma. The company sells products directly in the U.S. and through partnerships internationally.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Citius Oncology Inc stock.

Our verdict on CTOR

Not valued: We cannot value this company yet.

We do not publish a value for this company: it has no growth history of its own to project.

ETFs with the most weight in CTOR

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than CTOR in Drug Manufacturers - Specialty & Generic

33 more in this industry show a wider margin of safety.

Is CTOR undervalued or overvalued?

We do not publish a verdict on CTOR yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history. We do not have it. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of CTOR?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history. We do not have it. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.